+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PolyActiva Pty Ltd - Product Pipeline Analysis, 2021 Update

  • PDF Icon

    Company Profile

  • 29 Pages
  • February 2022
  • GlobalData
  • ID: 5552752
PolyActiva Pty Ltd (PolyActiva) is a biotechnology company that designs site-specific drug delivery products. It is developing glaucoma implant; endophthalmitis preventive and treatment implants; osteoarthritis gel; and NSAID (Non-steroidal anti-inflammatory) ocular implant. The company utilizes its platform technology to produce biomedical products, drug-delivery devices and device components which allows delivery of drugs directly to the affected organ or treatment site. PolyActiva works in partnership with Center for Eye research Australia, Bolder BioPATH Inc, Monash University and others. It is funded by Brandon Capital Partners and Yuuwa Capital LP. The company operates laboratories in Parkville, Victoria, Australia. PolyActiva is headquartered in Melbourne, Victoria, Australia.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company PolyActiva Pty Ltd
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

PolyActiva Pty Ltd Company Overview
  • PolyActiva Pty Ltd Company Snapshot
  • PolyActiva Pty Ltd Pipeline Products and Ongoing Clinical Trials Overview
  • PolyActiva Pty Ltd - Pipeline Analysis Overview
  • PolyActiva Pty Ltd - Key Facts
  • PolyActiva Pty Ltd - Major Products and Services
  • PolyActiva Pty Ltd Pipeline Products by Development Stage
  • PolyActiva Pty Ltd Ongoing Clinical Trials by Trial Status
  • PolyActiva Pty Ltd Pipeline Products Overview
  • Drug-Eluting Fibres
  • Drug-Eluting Fibres Product Overview
  • Endophthalmitis Preventive Implant
  • Endophthalmitis Preventive Implant Product Overview
  • Endophthalmitis Treatment Implant
  • Endophthalmitis Treatment Implant Product Overview
  • Intra-Articular Gel Implant - Osteoarthritis
  • Intra-Articular Gel Implant - Osteoarthritis Product Overview
  • Latanoprost FA SR Ocular Implant - Primary Open-Angle Glaucoma
  • Latanoprost FA SR Ocular Implant - Primary Open-Angle Glaucoma Product Overview
  • Latanoprost FA SR Ocular Implant - Primary Open-Angle Glaucoma Clinical Trial
  • NSAID Ocular Implant
  • NSAID Ocular Implant Product Overview
  • PolyActiva Pty Ltd - Key Competitors
  • PolyActiva Pty Ltd - Key Employees
  • PolyActiva Pty Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries

Recent Developments
  • PolyActiva Pty Ltd, Recent Developments
  • Oct 30, 2020: PolyActiva appoints Tracy Valorie, ophthalmic industry expert and former Bausch + Lomb executive, to its Board of Directors
  • Jul 23, 2019: PolyActiva completes recruitment in key phase I glaucoma implant safety study. six-month treatment period demonstrated.
  • Aug 30, 2018: PolyActiva commences Its first phase I clinical trial with potential to improve daily lives of millions of glaucoma patients

Appendix
  • Methodology
  • About the Publisher
  • Contact the Publisher
  • Disclaimer

List of Tables
  • PolyActiva Pty Ltd Pipeline Products and Ongoing Clinical Trials Overview
  • PolyActiva Pty Ltd Pipeline Products by Equipment Type
  • PolyActiva Pty Ltd Pipeline Products by Indication
  • PolyActiva Pty Ltd Ongoing Clinical Trials by Trial Status
  • PolyActiva Pty Ltd, Key Facts
  • PolyActiva Pty Ltd, Major Products and Services
  • PolyActiva Pty Ltd Number of Pipeline Products by Development Stage
  • PolyActiva Pty Ltd Pipeline Products Summary by Development Stage
  • PolyActiva Pty Ltd Ongoing Clinical Trials by Trial Status
  • PolyActiva Pty Ltd Ongoing Clinical Trials Summary
  • Drug-Eluting Fibres - Product Status
  • Drug-Eluting Fibres - Product Description
  • Endophthalmitis Preventive Implant - Product Status
  • Endophthalmitis Preventive Implant - Product Description
  • Endophthalmitis Treatment Implant - Product Status
  • Endophthalmitis Treatment Implant - Product Description
  • Intra-Articular Gel Implant - Osteoarthritis - Product Status
  • Intra-Articular Gel Implant - Osteoarthritis - Product Description
  • Latanoprost FA SR Ocular Implant - Primary Open-Angle Glaucoma - Product Status
  • Latanoprost FA SR Ocular Implant - Primary Open-Angle Glaucoma - Product Description
  • Latanoprost FA SR Ocular Implant - Primary Open-Angle Glaucoma - A Phase IIa Study Evaluating the Minimum Effective Dose of PA5108 Ocular Implant in Subjects with Mild to Moderate Primary Open-angle Glaucoma
  • Latanoprost FA SR Ocular Implant - Primary Open-Angle Glaucoma - An Open Label, Comparative, Sequential-dose, Multi-center Study Involving Intracameral Administration of a PA5108 Latanoprost FA SR Ocular Implant into the Eye of Patients with Mild-moderate Glaucoma
  • NSAID Ocular Implant - Product Status
  • NSAID Ocular Implant - Product Description
  • PolyActiva Pty Ltd, Key Employees
  • PolyActiva Pty Ltd, Other Locations
  • Glossary

List of Figures
  • PolyActiva Pty Ltd Pipeline Products by Equipment Type
  • PolyActiva Pty Ltd Pipeline Products by Development Stage
  • PolyActiva Pty Ltd Ongoing Clinical Trials by Trial Status

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Molteno Ophthalmic Ltd
  • Bionic Vision Technologies Pty Ltd
  • Allergan Australia Pty Ltd